![]() |
|
|
Argolyn Bioscience receives fifth US patentMar. 1, 2005 Swamp Fox
“This patent completes the second series of compounds devised by Dr. Dix, and creates a sizeable footprint around the intellectual property that is key to Argolyn’s future growth,” said Pearce Gilbert, president of Argolyn Bioscience. “Foreign equivalents are still pending, but the success in prosecuting the US cases suggests a good probability that the foreign cases also will issue in due course.” Argolyn Bioscience Inc. Argolyn Bioscience Inc. is a peptide drug development company headquartered in North Charleston, South Carolina. Argolyn is the exclusive worldwide licensee for a portfolio of patents and patent applications aimed at improving the pharmacology of peptide drug candidates. The company has one product in preclinical development and several other discovery stage pharmaceutical product programs. Argolyn Bioscience continues to seek other opportunities to disseminate the technology either through collaboration or out-licensing. For more information, contact the company or visit the website at www.argolyn.com. For More Information, Contact: Pearce Gilbert Argolyn Bioscience Inc. Tel: (843) 266-0851 Fax: (843) 266-0894 info@argolyn.com |
![]() |